UBITUS
Ubitus K.K. (hereinafter Ubitus), a leading cloud gaming technology provider, is thrilled to announce its participation in Viva Technology 2024, Europe’s biggest startup and tech event, taking place from May 22nd to May 25th at Paris Expo Porte de Versailles. Visitors can explore Ubitus' innovative solutions at Booth D38 in the TTA Pavilion, Hall 1, where you can express your creativity through Ubitus’ AI solutions.
Innovative Demonstrations at the Ubitus Booth
Ubitus is excited to showcase its AI technologies that increase creativity and productivity for everyone, including the debut of Ubi-chan in French and UbiArt, its visual art AI generative tool. Ubi-chan, Ubitus' AI V-tuber, will engage with attendees, providing an interactive experience that highlights the capabilities of AI in entertainment. Additionally, Ubitus will unveil UbiArt at the event, featuring unique “local style models” like the Taiwan Night Market, demonstrating the versatile applications of its technology in creating culturally rich digital art.
Keynote Speeches by CEO Wesley Kuo
Cloud vs Console: The Future of Gaming Platforms
Highlighting Ubitus' involvement, CEO Wesley Kuo will take the stage as an official speaker at VivaTech. Wesley Kuo is scheduled to present on "Cloud vs Console: The Future of Gaming Platforms" on May 23, from 9:45 AM to 10:30 AM on Stage 2. His speech session with Michael Fan, partner of Galaxy Interactive, and Joe Tidy, Cyber Correspondent of BBC News will address crucial topics in the gaming industry, discussing the transformative potential of cloud technology over traditional console platforms, impacts on market dynamics, the benefits of subscription-based models, and the implications for data privacy and game diversity. For more details on the session, please visit: https://vivatechnology.com/sessions/4a3a33b1-f2f0-ee11-aaf0-000d3a2b945f.
Introduction to Ubitus' AI Solutions
In addition, Wesley Kuo will deliver a second presentation on the main stage in the TTA Pavilion(Booth D38) at 2 PM on the same day, focusing on Ubitus' AI-driven initiatives.
Ubitus' participation in VivaTech 2024 showcases its commitment to innovation and its role in shaping the future of digital entertainment and AI applications. By introducing AI solutions like Ubi-chan, who will engage visitors in French, and UbiArt, which captures the essence of local cultures, showcasing the vibrant Taiwanese food culture, Ubitus is set to make a significant impact at this global tech event.
Join us at Viva Technology 2024 to experience the future of technology with Ubitus' innovative solutions. We look forward to welcoming you to our booth and sharing our vision for a connected world. For more information, please visit Ubitus K.K. website.
About Ubitus K.K.
Ubitus K.K. is a technology company that specializes in cloud solutions, GPU virtualization technology, and cloud streaming platform. Our focus is on delivering exceptional cloud and artificial intelligence services.
Leveraging the power of GPUs, Ubitus has developed multiple AI solutions, including UbiGPT (Taiwan LLM), Ubi Anchor (AI anchor), Ubi-chan (AI character), and UbiArt (image generation software). Ubitus is committed to delivering tailor-made solutions designed to meet the diverse requirements of customers in various industries. Our goal is to seamlessly incorporate a range of AI applications into distinctive situations, ensuring a customized approach for each use case.
Ubitus’ cloud gaming solution enables users to enjoy AAA gaming experiences across devices with just an internet connection. Through our comprehensive Game Development Kit (GDK), we offer patented technology for rapid deployment, catering towards international clients that are interested in cloud gaming, including console gaming platforms, telecom operators, and game developers.
For Metaverse solutions, Ubitus possesses extensive global cloud deployment experience via GameCloud® technology offerings. Ubitus is able to stream interactive media content for platform operators and digital content developers on multi-devices, which offers users an immersive experience that accelerates metaverse popularization.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515534843/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom